Sugi Predict

Sugi Predict / Compounds / SCHEMBL20128979

SCHEMBL20128979

SCHEMBL20128979

Brc1ccc(O[C@H]2C[C@H](Oc3cccc(OCCCCCCOC4CCCCO4)c3)C2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ KDM4C Q9H3R0 1/20 0.42
▸ DHFR P00374 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ DGAT1 O75907 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ LNPEP Q9UIQ6 1/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ P2RX3 P56373 1/20 0.30
▸ TGFBR1 P36897 1/20 0.30
▸ TGFBR2 P37173 1/20 0.30
▸ ALDH1A1 P00352 2/20 0.30
▸ TSHR P16473 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20128930 0.88 MEN1 (0.44) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL20128959 0.88 MEN1 (0.44) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL20128978 0.81 MEN1 (0.50) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL20128981 0.81 MEN1 (0.53) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL30993048 0.80 MEN1 (0.48) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL20120607 0.79 MEN1 (0.48) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL20120609 0.79 MEN1 (0.48) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL29548025 0.79 MEN1 (0.48) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL21911537 0.78 MEN1 (0.47) MEN1KMT2AKDM4CDHFRNPC1
SCHEMBL20129130 0.78 MEN1 (0.35) MEN1KMT2AKDM4CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 — — WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MEN1 1944/4885KMT2A 1250/4885KDM4C 2111/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885KDM4C 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.